Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Raloxifene

J A Balfour1, K L Goa

  • 1Adis International Limited, Auckland, New Zealand. demail@adis.co.nz

Drugs & Aging
|May 8, 1998
PubMed
Summary
This summary is machine-generated.

Selective estrogen receptor modulators like raloxifene benefit bone health and lipid levels in postmenopausal women. However, raloxifene carries an increased risk of venous thromboembolic events.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Velnacrine in Alzheimer's Disease : An Initial Appraisal of its Clinical Potential.

CNS drugs·2016
Same author

Levetiracetam.

CNS drugs·2013
Same author

Paroxetine : a review of its pharmacology and therapeutic potential in the management of panic disorder.

CNS drugs·2013
Same author

Adjuvanted influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Liposomal influenza vaccine.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same author

Becaplermin.

BioDrugs : clinical immunotherapeutics, biopharmaceuticals and gene therapy·2007
Same journal

Targeted Treatment for Hyperuricemia: The Drug Pipeline.

Drugs & aging·2026
Same journal

Efficacy and Safety of Ciprofol Versus Propofol for Anesthesia in Older Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials.

Drugs & aging·2026
Same journal

Leveraging Real-World Data for Clinical Decision Making in Geriatric Oncology.

Drugs & aging·2026
Same journal

Drug Utilisation of Fall-Risk-Increasing Drugs (FRIDs) and Risk of Hospitalisation: A Nested Case-Control Study Among Community-Dwelling Older Adults.

Drugs & aging·2026
Same journal

Gabapentinoid Use and Risk of Alzheimer's Disease-Related Dementias: A Systematic Review and Meta-analysis of Observational Studies.

Drugs & aging·2026
Same journal

Development and Validation of Prescribing Appropriateness Criteria (PAC) for Sri Lankan Older Adults.

Drugs & aging·2026
See all related articles

Area of Science:

  • Pharmacology
  • Endocrinology
  • Oncology

Background:

  • Selective estrogen receptor modulators (SERMs) offer tissue-specific estrogenic effects.
  • Raloxifene mimics estrogen's beneficial actions on bone and lipids.
  • Raloxifene exhibits anti-proliferative effects on breast cancer cells and mammary tumors.

Purpose of the Study:

  • To evaluate raloxifene's efficacy and safety in postmenopausal women.
  • To compare raloxifene with conjugated estrogens regarding bone metabolism.
  • To assess raloxifene's impact on endometrial proliferation.

Main Methods:

  • Clinical studies in postmenopausal women.
  • Comparative trials with conjugated estrogens.
  • In vitro and in vivo cancer cell proliferation assays.

Related Experiment Videos

Main Results:

  • Raloxifene significantly increased bone mineral density compared to placebo.
  • Raloxifene showed more modest effects on bone turnover than conjugated estrogens.
  • Raloxifene did not induce endometrial proliferation, unlike conjugated estrogens.

Conclusions:

  • Raloxifene is effective for improving bone mineral density in postmenopausal women.
  • Raloxifene presents a different risk-benefit profile compared to conjugated estrogens.
  • Raloxifene is a viable option for managing menopausal symptoms and bone loss without increasing endometrial cancer risk.